Pyruvate kinase-M2 (PKM2) is a major oncogenic ATP-generating glycolytic enzyme and is particularly overexpressed in pancreatic cancer.12–17 PKM2 has a low catalytic activity, producing a bottleneck at the terminal end of glycolysis.12,18 This is advantageous to cancer cells as it results in the buildup of glycolytic intermediates, which are then utilised in nucleotide and lipid biosynthesis to aid rapid proliferation. This evidence concerns the gene PKM and pancreatic neoplasm.